My Companies
Notification
Account
Log Out
Login
Board meeting on August 12, 2026 will consider unaudited standalone Q1 FY2027 results and evaluate fundraising through equity shares, warrants, preferential issue, private placement, rights issue or other permitted methods, subject to approvals.
Aspira Pathlab Approves ₹65 Crore Rights Issue Subject To Approvals
Aspira Approves ₹65 Crore Rights Issue Subject To Approvals
Aspira Pathlab & Diagnostics Board Approves ₹65 Crore Rights Issue
Aspira Pathlab & Diagnostics Approves ₹65 Crore Rights Issue Subject To Approvals
Aspira Pathlab Schedules September 12 Board Meeting To Consider Fundraising